Plain-English translation of NCT06656702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing , a medication being studied for its potential to help people with ALS who are struggling with depression. The researchers want to understand whether this treatment is safe and feasible to use in this patient population, and whether it might improve depression, quality of life, and overall well-being.
Depression is common in people with ALS and can significantly affect quality of life. Current treatments for depression don't work well for everyone, so researchers are exploring whether this medication might offer a new option for patients with ALS who are struggling with depressed mood.
You likely qualify if…
You likely don't qualify if…
Over 8 weeks, you would receive two doses of the medication (15 mg in week 4, and 15 or 25 mg in week 6), with professional support during each session. After the treatment period ends, you would return for follow-up assessments at 1 month, 3 months, and 6 months to check how you're doing and whether the treatment has helped your mood and quality of life.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Johns Hopkins University
Collaborators
United States Department of Defense, Congressionally Directed Medical Research Programs
Enrollment target
~24 participants
Started
April 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Betsy Mosmiller
Johns Hopkins University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.